Drugdiscovery >> Drugs >> News
6575
Views
Cancer muscle wasting drug fails in late stage clinical trial - drugdiscovery.com
Cancer muscle wasting drug fails in late stage clinical trial - drugdiscovery.com


GTx ‘drug enobosarm is designed to prevent or treat muscle wasting in cancer patients. Currently, there are no drugs approved for treatment of this condition. In a late-stage clinical trial in patients with advanced forms of non-small cell lung cancer enobosarm fell short of some main goals.
Read More >>


Tags: muscle wasting, drug, cancer, enobosarm, GTx, cancer cachexia - August 21, 2013
Related Articles
5287
Views
Novartis AG drug might be a blockbuster - late stage test proved Novartis AG drug might be a blockbuster - late stage test proved
Jakavi, ruxolitinib drug of Novartis has produced nice results in patients with myelofibrosis. Patients with at least years of treatment said that their life quality improved significantly. Read More >>

Tags: Novartis, myelofibrosis, Jakavi, late-stage

4365
Views
Depression drug  fails in Phase 2 clinical trials Depression drug fails in Phase 2 clinical trials
Bristol-Myers Squibb/ Albany Molecular Research drug, BMS-820836 was intended for treatment resistant depression in which patients did not respond to other therapies on the market. But, since it sho Read More >>

Tags: depression, drugs, new treatment, clinical trial,Bristol-Myers Squibb, Albany Molecular Research

5882
Views
Gilotrif Approved for Late-Stage Lung Cancer Gilotrif Approved for Late-Stage Lung Cancer
The U.S. Food and Drug Administration approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth Read More >>

Tags: Gilotrif, metastatic non-small cell lung cancer

8727
Views
Novartis muscle drug gets breakthrough therapy designation Novartis muscle drug gets breakthrough therapy designation
The FDA granted a breakthrough therapy status to Novartis’ newly developed compound- bimagrumab (BYM338), used to treat a life-threatening muscle disease called sporadic inclusion body myositis tha Read More >>

Tags: Novartis, cancer cachexia,sarcopenia, COPD, bimagrumab, BYM338, sporadic inclusion body myositis, muscles, waste away

5822
Views
A positive review of  Roche’s  Perjeta in early stage breast cancer A positive review of Roche’s Perjeta in early stage breast cancer
The FDA has issued a positive review of Perjeta and recommended accelerating approval. In mid-stage trials, women with early-stage breast cancer who received the drug had significantly fewer tumor Read More >>

Tags: Perjeta, Roche, breast cancer, early stage, FDA, review

7291
Views
The most promising drugs in biopharma's  late-stage pipeline The most promising drugs in biopharma's late-stage pipeline
An expert’s opinion on which are the 10 most prospective drugs in the late-stage pipeline at this moment. Read More >>

Tags: top 10, most promising, drugs, prospective, biopharma, pipeline

4639
Views
Why combo cancer drugs fail at clinical trials Why combo cancer drugs fail at clinical trials
Combo cancer drugs are often prove to be ineffective when it comes to clinical trials. According to the latest researches this is because one drug makes the other ineffective. Can this problem be solv Read More >>

Tags: clinical trial, combo drugs

2954
Views
Clostridium difficile vaccine enters phase III clinical trial Clostridium difficile vaccine enters phase III clinical trial
Sanofi Pasteur is will recruit up to 15000 adults aged 50 or older and planning an upcoming hospitalisation or have had at least two hospital stays and have received systemic antibiotics in the past y Read More >>

Tags: Sanofi, vaccine, Clostridium difficile, C. diff, clinical trial

4053
Views
Yervoy misses study goal in the treatment of advanced prostate cancer Yervoy misses study goal in the treatment of advanced prostate cancer
Bristol-Myers Squibb Co.'s drug for advanced melanoma, Yervoy , was tested as a treatment for advanced prostate cancer but did not achieve statistically significant improvement in overall survival c Read More >>

Tags: yervoy, prostate cancer, melanoma, advanced, treatment, Bristol-Myers Squibb, clinical trial

5188
Views
Two-drug therapy more effective than Enbrel monotherapy in RA Two-drug therapy more effective than Enbrel monotherapy in RA
According to a latest clinical trial, combined therapy of Enbrel (etanercept) and methotrexate in patients with rheumatoid arthritis (RA) is more effective than monotherapy with Enbrel. Read More >>

Tags: enbrel, etanercept, methotrexate, rheumatoid artritis, RA, monotherapy, two-drug therapy, clinical trial

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013